Wednesday, March 11, 2026

BioNTech co-founders to launch new next-gen mRNA company

BioNTech has announced plans for its co-founders, Prof. Ugur Sahin and Prof. Özlem Türeci, to establish an independent biotechnology company focused on next-generation mRNA innovations. BioNTech said the two intend to transition into management roles at the new company by the end of 2026.

At the same time, BioNTech said it will further refine its strategic focus and push ahead with development and commercialization of its expanding late-stage pipeline across immunomodulators, antibody-drug conjugates (ADCs), and mRNA candidates. The company stated that its current clinical programs, previously communicated milestones, and its COVID-19 vaccine franchise are not affected by the planned new venture.

Planned structure: minority stake and contribution of rights

BioNTech plans to contribute certain rights and mRNA technologies to the new company. In return, BioNTech expects to receive a minority stake as well as additional consideration, including milestone payments and royalties. The companies are expected to pursue distinct strategic priorities, while retaining the option to collaborate on potential combination approaches involving their respective product candidates.

BioNTech said it expects binding agreements to be signed by the end of the first half of 2026, with further details to be shared after definitive contracts are executed.

Management transition and succession process

In light of the planned transition, BioNTech said its Supervisory Board has initiated an executive search to identify successors and support a smooth handover while keeping the company’s strategy on track.

Oncology focus and 2026 late-stage readouts

BioNTech expects to have 15 ongoing Phase 3 clinical trials in oncology by year end. The company also said 2026 is expected to be the first year with multiple late-stage data readouts across major cancer types, intended to inform regulatory and launch planning.

The announcement was published on March 10, 2026 by BioNTech (Nasdaq: BNTX). More details are available via the company’s website.